Serum HBV DNA level at week 24 as a proper predictor for the effect of 2-year lamivudine treatment

Chinese Medical Journal

Volumn 124, Issue 8, 2011, Pages 1257-1260

  Zheng, Qi ^a   Jiang, Jia Ji ^a   Chen, Jing ^a   Zhu, Yue Yong ^a   Liu, Yu Rui ^a   Chen, You Tao ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Drug resistance; Hepatitis B virus DNA; Lamivudine; Predictor

Indexed keywords

LAMIVUDINE; VIRUS DNA;

ADOLESCENT; AGED; ARTICLE; BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955487019     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.08.025     Document Type: Article

References (11)

1. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
2. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696.
3. Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009; 3: 425-433.
4. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075.
5. Yuen MF, Wong DK, Fung J, Fong DY, Yuen JC, Lai CL. Predictive value of HBV DNA Levels at frequent time points during early and maintenance phase of 5-year Lamivudine and mutational profiles of reverse transcriptase (RT)and surface (S) genes. Hepatology 2006; 44 (Suppl 1): 557A.
6. Nishida T, Kobashi H, Fujioka S, Fujio K, Takaguchi K, Ikeda H, et al. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol 2008; 23: 794-803.
7. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46: 1695-1703.
8. Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13: 4085-4090.
9. Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Kao JH, et al. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. Liver Int 2008; 28: 1034-1041.
10. Thompson AJ, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol 2007; 22: 1078-1085.
11. Gaia S, Barbon V, Smedile A, Olivero A, Carenzi S, Lagget M, et al. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol 2008; 48: 540-547.